Brands: Drizalma Sprinkle · Duloxetine Hydrochloride
Average across 51 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Bryant Ranch Prepack | repackager | 51 | SUPPLYING |
| Asclemed USA, Inc. | repackager | 35 | SUPPLYING |
| SUN PHARMACEUTICAL INDUSTRIES, INC. | generic | 33 | SUPPLYING |
| REMEDYREPACK INC. | repackager | 32 | SUPPLYING |
| Preferred Pharmaceuticals Inc. | repackager | 22 | SUPPLYING |
| Alembic Pharmaceuticals Limited | generic | 20 | SUPPLYING |
| Camber Pharmaceuticals, Inc. | generic | 19 | SUPPLYING |
| A-S Medication Solutions | repackager | 16 | SUPPLYING |
| HAWAII REPACK, INC | repackager | 16 | SUPPLYING |
| Inventia Healthcare Limited. | unknown | 15 | SUPPLYING |
| Ascend Laboratories, LLC | generic | 13 | SUPPLYING |
| Proficient Rx LP | repackager | 12 | SUPPLYING |
| Ajanta Pharma USA Inc. | unknown | 11 | SUPPLYING |
| Solco Healthcare US, LLC | unknown | 10 | SUPPLYING |
| Lupin Pharmaceuticals,Inc. | generic | 9 | SUPPLYING |
+ 18 more labelers
Shortages, recalls, and registration changes attached to this drug concept.
CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit. — Recalling firm: Asclemed USA Inc. — US Nationwide.
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals. — Recalling firm: Ajanta Pharma Ltd. — Nationwide within U.S
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals. — Recalling firm: Ajanta Pharma Ltd. — Nationwide within U.S
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals. — Recalling firm: Ajanta Pharma Ltd. — Nationwide within U.S
Failed Dissolution Specification — Recalling firm: Lupin Pharmaceuticals Inc. — Nationwide within the United States
